Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Related topics
Speaker: Silvester J. Bartsch, Department of Biomedical Imaging and Image-guided Therapy,
Medical University of Vienna, Vienna, Austria
Silvester J. Bartsch studied evolutionary biology at the Department of Theoretical Biology, University of Vienna, before he started his PhD-research project at the Department of Biomedical Imaging and Image-guided Therapy and the Medical University of Vienna. His current research aims at the characterization of niches within the hypoxic tumor microenvironment of breast cancer using simultaneous multiparametric PET/MR imaging. To this end, he combines [18F]FDG and [18F]FMISO PET with multiparametric MRI (diffusion-weighted MRI, blood oxygen level dependent MRI, glucose-enhanced CEST-MRI, dynamic contrast enhanced MRI) for the characterization the hypoxia-induced reprogramming of glucose metabolism, as well as the induction of angiogenesis, which are important hallmarks in breast cancer progression.
Related technologies: PET, SPECT, CT
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
http://www.bruker.com